Tissue Procurement Core

组织采购核心（TPC）共享资源：项目总结 Siteman癌症中心（SCC）组织采购核心（TPC）是美国病理学家协会 （CAP）-认可的共享实验室资源，可使用人体组织进行基于患者的癌症研究 和生物流体。TPC为患者组织和液体标本采集提供高成本效益的服务， 处理、跟踪和存储，以支持机构和多机构， 治疗性临床试验TPC还提供生物标本资源和专业知识， 将科学发现转化为临床相关的转化癌症研究。这包括简化和透明 访问手术切除的冷冻肿瘤和患者匹配的非恶性实体的存档集合 来自同意的癌症患者的组织（外周血细胞、血清和血浆），组织组织学服务 病理学家咨询、核酸（RNA / DNA）分离和质量保证。在过去的五年里， TPC已经收集和处理了20多万份用于临床试验和翻译的人类生物标本， 为SCC成员提供研究。技经会支助的活动产生了50多份经同行审查的出版物， 其中近一半发表在高影响力期刊上（汤姆森路透社影响因子为10或 更大）。TPC还在全国范围内为国家生物标本和科学领导做出了贡献。 癌症研究所基于生物标志物的倡议，如临床蛋白质组学肿瘤分析联盟 （CPTAC），标本资源库（SRL）和国家临床试验网络（NCTN）。下一个项目 在此期间，将继续强调开发和标准化最先进的生物标本 用于无细胞DNA、单细胞分析、外泌体和宏基因组学的处理和储存方法，以支持 “下一代”转化癌症研究。

TISSUE PROCUREMENT CORE (TPC) SHARED RESOURCE: PROJECT SUMMARY The Siteman Cancer Center (SCC) Tissue Procurement Core (TPC) is a College of American Pathologists (CAP)-accredited shared laboratory resource that enables patient-based cancer research using human tissues and biofluids. The TPC provides highly cost-effective services for patient tissue and fluid specimen collection, processing, tracking, and storage in order to support institutional and multi-institutional, investigator-initiated therapeutic clinical trials. The TPC also provides biospecimen resources and expertise to rapidly transform basic science discoveries into clinically relevant translational cancer research. This includes simplified and transparent access to an archived collection of surgically resected frozen tumor and patient-matched non-malignant solid tissues (peripheral blood cells, serum, and plasma) from consenting cancer patients, tissue histology services and pathologist consultation, nucleic acid (RNA / DNA) isolation, and quality assurance. Over the past five years, the TPC has collected and processed over 200,000 human biospecimens for clinical trials and translational studies for SCC members. TPC-supported activities have resulted in more than 50 peer-reviewed publications, almost half of which have been published in high impact journals (Thomson Reuters impact factor of 10 or greater). The TPC has also contributed biospecimens and scientific leadership on a national scale to National Cancer Institute biospecimen-based initiatives such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), Specimen Resource Locator (SRL), and National Clinical Trials Network (NCTN). Over the next project period, continuing emphasis will be placed on developing and standardizing state-of-the-art biospecimen processing and storage methods for cell-free DNA, single cell analysis, exosomes, and metagenomics to support ‘next-generation’ translational cancer research.